Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
4 Leser
Artikel bewerten:
(0)

ResMed Innovation Excellence Earns Two Red Dot Design Awards For 2014

-- Dual Win Highlights Innovation in Patient-Centric Design

SAN DIEGO, April 14, 2014 /PRNewswire/ --ResMed(NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other respiratory conditions,has won two Red Dot Product Design Awards for 2014 - one for its AirFit' P10 nasal pillows mask and one for its soon-to-be-launched Astral' 150 life support ventilator. A repeat winner, having been recognized in 2010 for its S9' Series, ResMed's products have built a global reputation for their sophisticated and life-improving technology, with simple, elegant design.

Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a

Red Dot is the world's largest and most renowned design competition. This year, 4,815 entries were submitted by manufacturers, designers, and architects from 53 countries, with only 1,120 earning the prestigious designation.

"From our masks and positive airflow pressure (PAP) devices to our ventilators and diagnostic equipment, ResMed has a proud 25-year history of delivering innovative solutions with the patient's comfort and well-being in mind," said Mick Farrell, ResMed CEO. "The AirFit P10 and Astral 150 are both backed by decades of science and clinical research as we remain focused on three key goals: improving patient quality of life, preventing progression of chronic diseases, and lowering total healthcare costs."

Launched in January 2014, the ultra-light, ultra-quiet AirFit P10 nasal pillows mask weighs just 1.6 ounces, and has only three parts, including a mesh vent called QuietAir' that makes it 50 percent quieter than its predecessor.The AirFit P10, used in conjunction with a PAP device to treat sleep apnea, has been found by ResMed to provide patients with an average of 40 more minutes of sleep per night. Lack of healthy breathing during sleep is linked to a number of serious health conditions and is known to affect one's overall well-being and quality of life.

The soon-to-be-launched Astral 150 life support ventilator is a small, portable, and lightweight system with extended battery life, and patient-friendly set-up and operation. These features allow chronically ill adult and pediatric patients, who would otherwise be hospitalized, to be safely treated outside the hospital for various respiratory conditions. In particular, the Astral 150 provides respiratory help for patients suffering from the effects of neuromuscular disease, chronic obstructive pulmonary disease, and other adult and childhood breathing disorders.

AboutResMed:
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:




For News Media

For Investors

Troy Anderson

David Pendarvis

Manager, Global Corporate Communications

Chief Administrative Officer and Global

O: +1-858-836-6772

General Counsel

news@resmed.com

O: +1-858-836-5000


investor.relations@ResMed.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.